Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

AMD Leading On Desktop and Server Market, but Don’t Count Intel Out

By Chris Lau, InvestorPlace Contributor

AMD is releasing impressive desktop and server CPUs that will take Intel's market share. Don't count out Intel, though, thanks to Mobileye.

Can Amazon Stock Really Trade at $3000 a Share?

By Chris Lau, InvestorPlace Contributor

With Amazon.com competing so effectively in all of its markets, $3,000 could be a reasonable price for AMZN stock in the not-so-distant future.

5 Reasons to Buy Gilead Stock Today

By Chris Lau, InvestorPlace Contributor

Investors are on the sidelines with Gilead stock, but the wait could be over. A strong pipeline ahead will drive GILD revenue higher.

AMD Stock Is Pricey but May Be Completely Unstoppable

By Chris Lau, InvestorPlace Contributor

Advanced Micro Devices earned many bullish analyst reports in the last two weeks. You may want to wait for a dip, but AMD stock is a buy.

IQ Stock Might Be Worth a Look If You Can Handle the Bumps

By Chris Lau, InvestorPlace Contributor

Trade tensions will ease, and IQ stock is set to grow

3 High Dividend Stocks to Buy for Safety in Your Portfolio

By Chris Lau, InvestorPlace Contributor

Dividend stocks give investors a source of steady money. These 3 stocks are also 'safety' stocks -- so their dividends aren't going anywhere.

There’s More to Like About MSFT Stock Than a Likely Dividend Bump

By Chris Lau, InvestorPlace Contributor

Microsoft is generating tremendous cash flow growth and higher profit margins. Higher dividends for MSFT are on the way, too.

7 Biotech Stocks to Buy Now

By Chris Lau, InvestorPlace Contributor

Biotech companies are recovering nicely this year. With a quarter left to go, the upside potential is high for those biotech stocks that dipped recently.

Teva Wins Approval From FDA for Blockbuster Migraine Drug

By Chris Lau, InvestorPlace Contributor

The markets are ignoring the potential sales growth for Teva's migraine drug. Value investors should look at Teva stock now.

Cronos Gets Bigger As It Partners With Ginkgo Bioworks

By Chris Lau, InvestorPlace Contributor

Cronos is expanding its addressable market by entering into a joint partnership with Ginkgo Bioworks, which is good news for CRON stock.

Load More